Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
38
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Adams Chandra | Deputy GC | 7 | $0 | $3.7K | 2023-09-08 |
| RATH HENRY C. | Chief Business Officer | 7 | $0 | $9.8K | 2023-09-08 |
| FEES JESSICA | See Remarks | 34 | $0 | $175.7K | 2023-09-08 |
| ROSS ROBERT W. | Chief Medical Officer | 22 | $0 | $428.6K | 2023-09-08 |
| GRAYZEL DAVID S. | Director | 12 | $1.50M | $44.54M | 2023-09-08 |
| Sigal Charles Elliott | Director | 11 | $0 | $0 | 2023-09-08 |
| Goater Jeff | Director | 28 | $16.1K | $2.82M | 2023-09-08 |
| Palombella Vito J. | Chief Scientific Officer | 11 | $0 | $168.3K | 2023-09-08 |
| ONEILL ALISON | Chief Medical Officer | 10 | $0 | $104.6K | 2023-09-08 |
| Brunn Carsten | Director | 1 | $0 | $0 | 2022-06-28 |
| Torres Denice | Director | 3 | $0 | $0 | 2022-06-08 |
| Ibrahim Ramy | Director | 4 | $0 | $0 | 2022-06-08 |
| Hickey Benjamin | Director | 2 | $0 | $0 | 2022-06-08 |
| Shanafelt Armen | Director, 10% Owner | 9 | $3.99M | $0 | 2022-06-08 |
| Stelzer Laurie | Director | 4 | $0 | $0 | 2022-06-08 |
| Boni Theresa | General Counsel & Secretary | 1 | $0 | $0 | 2022-04-01 |
| Nogelo Liisa I | General Counsel | 6 | $0 | $160.6K | 2021-07-21 |
| MCDONOUGH GEOFF | Director | 5 | $0 | $0 | 2021-06-08 |
| Atlas Venture Fund IX, L.P. | 10% Owner | 1 | $0 | $30.77M | 2020-12-17 |
| Atlas Venture Associates IX, LLC | 10% Owner | 4 | $1.50M | $13.77M | 2020-12-17 |
| EcoR1 Capital, LLC | 10% Owner | 1 | $0 | $2.38M | 2020-09-01 |
| LYNCH DANIEL | Director | 2 | $0 | $0 | 2020-06-10 |
| Florence Anthony A. Jr. | 10% Owner | 4 | $2.00M | $1.54M | 2020-05-20 |
| Dwyer Wendy | Chief Business Officer | 4 | $0 | $0 | 2020-02-28 |
| FIL Ltd | Other | 2 | $0 | $0 | 2018-04-23 |
| FMR LLC | 10% Owner | 2 | $0 | $0 | 2018-04-23 |
| October 2017 Liquidating Trust | Other | 2 | $0 | $0 | 2018-04-23 |
| Novartis Institutes for BioMedical Research, Inc. | 10% Owner | 5 | $11.50M | $0 | 2018-04-23 |
| Hall Steven Edward | 10% Owner | 3 | $3.99M | $0 | 2018-04-23 |
| Sonsini Peter W. | 10% Owner | 3 | $2.00M | $0 | 2018-04-23 |
| New Enterprise Associates 14, L.P. | 10% Owner | 3 | $2.00M | $0 | 2018-04-23 |
| Viswanathan Ravi | 10% Owner | 3 | $2.00M | $0 | 2018-04-23 |
| BASKETT FOREST | 10% Owner | 3 | $2.00M | $0 | 2018-04-23 |
| SANDELL SCOTT D | 10% Owner | 3 | $2.00M | $0 | 2018-04-23 |
| KERINS PATRICK J | 10% Owner | 3 | $2.00M | $0 | 2018-04-23 |
| MOTT DAVID M | 10% Owner | 3 | $2.00M | $0 | 2018-04-23 |
| BARRETT M JAMES | 10% Owner | 3 | $2.00M | $0 | 2018-04-23 |
| BARRIS PETER J | 10% Owner | 3 | $2.00M | $0 | 2018-04-23 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| ONEILL ALISON | Chief Medical Officer | D To issuer deriv | 2023-09-08 | 2023-09-08 | 150,000 | — | $0 | 0 | SEC↗ |
| ROSS ROBERT W. | Chief Executive Officer | D To issuer deriv | 2023-09-08 | 2023-09-08 | 400,000 | — | $0 | 0 | SEC↗ |
| RATH HENRY C. | Chief Business Officer | D To issuer deriv | 2023-09-08 | 2023-09-08 | 150,000 | — | $0 | 0 | SEC↗ |
| Adams Chandra | Deputy GC | D To issuer deriv | 2023-09-08 | 2023-09-08 | 50,000 | — | $0 | 0 | SEC↗ |
| Adams Chandra | Deputy GC | D To issuer deriv | 2023-09-08 | 2023-09-08 | 50,000 | — | $0 | 0 | SEC↗ |
| Sigal Charles Elliott | Director | D To issuer deriv | 2023-09-08 | 2023-09-08 | 113,636 | — | $0 | 0 | SEC↗ |
| FEES JESSICA | Chief Financial Officer | D To issuer deriv | 2023-09-08 | 2023-09-08 | 150,000 | — | $0 | 0 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | D To issuer deriv | 2023-09-08 | 2023-09-08 | 150,000 | — | $0 | 0 | SEC↗ |
| ONEILL ALISON | Chief Medical Officer | D To issuer | 2023-09-08 | 2023-09-08 | 56,686 | — | $0 | 0 | SEC↗ |
| GRAYZEL DAVID S. | Director | D To issuer | 2023-09-08 | 2023-09-08 | 2,945,453 | — | $0 | 0 | SEC↗ |
| ROSS ROBERT W. | Chief Executive Officer | D To issuer | 2023-09-08 | 2023-09-08 | 83,193 | — | $0 | 0 | SEC↗ |
| Goater Jeff | Director | D To issuer | 2023-09-08 | 2023-09-08 | 129,222 | — | $0 | 0 | SEC↗ |
| RATH HENRY C. | Chief Business Officer | D To issuer | 2023-09-08 | 2023-09-08 | 44,971 | — | $0 | 0 | SEC↗ |
| Adams Chandra | Deputy GC | D To issuer | 2023-09-08 | 2023-09-08 | 23,884 | — | $0 | 0 | SEC↗ |
| Sigal Charles Elliott | Director | D To issuer | 2023-09-08 | 2023-09-08 | 45,453 | — | $0 | 0 | SEC↗ |
| FEES JESSICA | Chief Financial Officer | D To issuer | 2023-09-08 | 2023-09-08 | 101,915 | — | $0 | 0 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | D To issuer | 2023-09-08 | 2023-09-08 | 87,212 | — | $0 | 0 | SEC↗ |
| ROSS ROBERT W. | Chief Executive Officer | S Sale | 2023-08-01 | 2023-08-11 | 16,713 | $0.94 | $15.7K | 83,193 | SEC↗ |
| FEES JESSICA | Chief Financial Officer | S Sale | 2023-08-01 | 2023-08-11 | 9,434 | $0.94 | $8.9K | 101,915 | SEC↗ |
| Adams Chandra | Deputy GC | S Sale | 2023-08-01 | 2023-08-11 | 3,901 | $0.94 | $3.7K | 30,899 | SEC↗ |
| ONEILL ALISON | Chief Medical Officer | S Sale | 2023-08-01 | 2023-08-11 | 7,042 | $0.94 | $6.6K | 56,686 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | A Award deriv | 2023-03-01 | 2023-03-03 | 150,000 | — | $0 | 150,000 | SEC↗ |
| FEES JESSICA | Chief Financial Officer | A Award deriv | 2023-03-01 | 2023-03-03 | 150,000 | — | $0 | 150,000 | SEC↗ |
| ONEILL ALISON | Chief Medical Officer | A Award deriv | 2023-03-01 | 2023-03-03 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Adams Chandra | Deputy GC | A Award deriv | 2023-03-01 | 2023-03-03 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Adams Chandra | Deputy GC | A Award deriv | 2023-03-01 | 2023-03-03 | 50,000 | — | $0 | 50,000 | SEC↗ |
| ROSS ROBERT W. | Chief Executive Officer | A Award deriv | 2023-03-01 | 2023-03-03 | 400,000 | — | $0 | 400,000 | SEC↗ |
| RATH HENRY C. | Chief Business Officer | A Award deriv | 2023-03-01 | 2023-03-03 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Adams Chandra | Deputy GC | A Award deriv | 2022-11-01 | 2022-11-03 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | S Sale | 2022-08-03 | 2022-08-05 | 4,463 | $1.72 | $7.7K | 87,212 | SEC↗ |
| FEES JESSICA | Chief Financial Officer | S Sale | 2022-08-03 | 2022-08-05 | 5,980 | $1.72 | $10.3K | 111,349 | SEC↗ |
| ROSS ROBERT W. | Chief Executive Officer | S Sale | 2022-08-03 | 2022-08-05 | 10,594 | $1.72 | $18.2K | 99,906 | SEC↗ |
| ONEILL ALISON | Chief Medical Officer | S Sale | 2022-08-03 | 2022-08-05 | 4,463 | $1.72 | $7.7K | 63,728 | SEC↗ |
| RATH HENRY C. | Chief Business Officer | S Sale | 2022-08-03 | 2022-08-05 | 5,676 | $1.72 | $9.8K | 32,324 | SEC↗ |
| Brunn Carsten | Director | A Award deriv | 2022-06-28 | 2022-06-30 | 48,000 | — | $0 | 48,000 | SEC↗ |
| Goater Jeff | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| Ibrahim Ramy | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| Hickey Benjamin | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| Stelzer Laurie | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| Torres Denice | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| Shanafelt Armen | Director, 10% Owner | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| Sigal Charles Elliott | Director | A Award deriv | 2022-06-08 | 2022-06-10 | 24,000 | — | $0 | 24,000 | SEC↗ |
| Boni Theresa | General Counsel & Secretary | A Award deriv | 2022-04-01 | 2022-04-01 | 120,000 | — | $0 | 120,000 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | A Award deriv | 2022-03-01 | 2022-03-03 | 108,000 | — | $0 | 108,000 | SEC↗ |
| ONEILL ALISON | Chief Medical Officer | A Award deriv | 2022-03-01 | 2022-03-03 | 108,000 | — | $0 | 108,000 | SEC↗ |
| FEES JESSICA | Chief Financial Officer | A Award deriv | 2022-03-01 | 2022-03-03 | 108,000 | — | $0 | 108,000 | SEC↗ |
| RATH HENRY C. | Chief Business Officer | A Award deriv | 2022-03-01 | 2022-03-03 | 108,000 | — | $0 | 108,000 | SEC↗ |
| ROSS ROBERT W. | Chief Executive Officer | A Award deriv | 2022-03-01 | 2022-03-03 | 359,000 | — | $0 | 359,000 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | A Award | 2022-03-01 | 2022-03-03 | 38,000 | — | $0 | 91,675 | SEC↗ |
| ONEILL ALISON | Chief Medical Officer | A Award | 2022-03-01 | 2022-03-03 | 38,000 | — | $0 | 68,191 | SEC↗ |
| FEES JESSICA | Chief Financial Officer | A Award | 2022-03-01 | 2022-03-03 | 38,000 | — | $0 | 117,329 | SEC↗ |
| RATH HENRY C. | Chief Business Officer | A Award | 2022-03-01 | 2022-03-03 | 38,000 | — | $0 | 38,000 | SEC↗ |
| ROSS ROBERT W. | Chief Executive Officer | A Award | 2022-03-01 | 2022-03-03 | 56,000 | — | $0 | 110,500 | SEC↗ |
| Torres Denice | Director | A Award deriv | 2022-01-03 | 2022-01-05 | 12,000 | — | $0 | 12,000 | SEC↗ |
| Hickey Benjamin | Director | A Award deriv | 2022-01-03 | 2022-01-05 | 24,000 | — | $0 | 24,000 | SEC↗ |
| Torres Denice | Director | A Award deriv | 2021-08-02 | 2021-08-03 | 36,000 | — | $0 | 36,000 | SEC↗ |
| ONEILL ALISON | Chief Medical Officer | S Sale | 2021-07-21 | 2022-01-14 | 14,809 | $6.10 | $90.3K | 30,191 | SEC↗ |
| Nogelo Liisa I | Chief Legal Officer | S Sale | 2021-07-21 | 2022-01-14 | 26,325 | $6.10 | $160.6K | 53,675 | SEC↗ |
| ROSS ROBERT W. | Chief Executive Officer | S Sale | 2021-07-21 | 2022-01-14 | 33,500 | $6.10 | $204.3K | 54,500 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | S Sale | 2021-07-21 | 2022-01-14 | 26,325 | $6.10 | $160.6K | 53,675 | SEC↗ |
| FEES JESSICA | Chief Financial Officer | S Sale | 2021-07-21 | 2022-01-14 | 19,854 | $6.10 | $121.1K | 79,329 | SEC↗ |
| Goater Jeff | Director | S Sale | 2021-07-21 | 2022-01-14 | 127,778 | $6.10 | $779.4K | 129,222 | SEC↗ |
| Goater Jeff | Director | M Exercise deriv | 2021-06-11 | 2021-06-11 | 10,273 | — | $0 | 93,831 | SEC↗ |
| Goater Jeff | Director | M Exercise | 2021-06-11 | 2021-06-11 | 10,273 | $4.14 | $42.5K | 272,273 | SEC↗ |
| Goater Jeff | Director | S Sale | 2021-06-11 | 2021-06-11 | 15,273 | $7.61 | $116.2K | 257,000 | SEC↗ |
| Goater Jeff | Director | M Exercise deriv | 2021-06-10 | 2021-06-11 | 200,000 | — | $0 | 104,104 | SEC↗ |
| Goater Jeff | Director | M Exercise deriv | 2021-06-10 | 2021-06-11 | 34,727 | — | $0 | 10,325 | SEC↗ |
| Goater Jeff | Director | M Exercise | 2021-06-10 | 2021-06-11 | 34,727 | $4.14 | $143.8K | 496,727 | SEC↗ |
| Goater Jeff | Director | M Exercise | 2021-06-10 | 2021-06-11 | 200,000 | $4.14 | $828.0K | 462,000 | SEC↗ |
| Goater Jeff | Director | S Sale | 2021-06-10 | 2021-06-11 | 234,727 | $7.66 | $1.80M | 262,000 | SEC↗ |
| MCDONOUGH GEOFF | Director | A Award deriv | 2021-06-08 | 2021-06-10 | 17,700 | — | $0 | 17,700 | SEC↗ |
| Shanafelt Armen | Director, 10% Owner | A Award deriv | 2021-06-08 | 2021-06-10 | 17,700 | — | $0 | 17,700 | SEC↗ |
| Ibrahim Ramy | Director | A Award deriv | 2021-06-08 | 2021-06-10 | 17,700 | — | $0 | 17,700 | SEC↗ |
| Stelzer Laurie | Director | A Award deriv | 2021-06-08 | 2021-06-10 | 17,700 | — | $0 | 17,700 | SEC↗ |
| Sigal Charles Elliott | Director | A Award deriv | 2021-06-08 | 2021-06-10 | 17,700 | — | $0 | 17,700 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2021-06-08 | 2021-06-10 | 17,700 | — | $0 | 17,700 | SEC↗ |
| FEES JESSICA | See Remarks | A Award deriv | 2021-05-03 | 2021-05-05 | 30,000 | — | $0 | 30,000 | SEC↗ |
| RATH HENRY C. | Chief Business Officer | A Award deriv | 2021-05-03 | 2021-05-05 | 140,000 | — | $0 | 140,000 | SEC↗ |
| ONEILL ALISON | CHIEF MEDICAL OFFICER | A Award deriv | 2021-05-03 | 2021-05-05 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Goater Jeff | Director | A Award deriv | 2021-04-01 | 2021-04-02 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Goater Jeff | Director | A Award deriv | 2021-04-01 | 2021-04-02 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Goater Jeff | Director | A Award deriv | 2021-04-01 | 2021-04-02 | 35,400 | — | $0 | 35,400 | SEC↗ |
| Goater Jeff | Director | A Award deriv | 2021-04-01 | 2021-04-02 | 4,425 | — | $0 | 4,425 | SEC↗ |
| FEES JESSICA | See Remarks | A Award deriv | 2021-03-01 | 2021-03-03 | 68,000 | — | $0 | 68,000 | SEC↗ |
| Nogelo Liisa I | Chief Legal Officer | A Award deriv | 2021-03-01 | 2021-03-03 | 82,000 | — | $0 | 82,000 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | A Award deriv | 2021-03-01 | 2021-03-03 | 82,000 | — | $0 | 82,000 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | S Sale | 2021-02-16 | 2021-02-18 | 1,000 | $11.35 | $11.3K | 88,000 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | A Award deriv | 2021-02-12 | 2021-03-03 | 484,280 | — | $0 | 484,280 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | A Award deriv | 2021-02-12 | 2021-03-11 | 484,280 | — | $0 | 484,280 | SEC↗ |
| Goater Jeff | Chief Executive Officer | M Exercise deriv | 2021-02-08 | 2021-02-09 | 2,500 | — | $0 | 247,000 | SEC↗ |
| Goater Jeff | Chief Executive Officer | S Sale | 2021-02-08 | 2021-02-09 | 2,500 | $12.50 | $31.3K | 262,000 | SEC↗ |
| Goater Jeff | Chief Executive Officer | M Exercise | 2021-02-08 | 2021-02-09 | 2,500 | $3.18 | $8.0K | 264,500 | SEC↗ |
| FEES JESSICA | See Remarks | S Sale | 2021-02-08 | 2021-02-09 | 1,500 | $12.45 | $18.7K | 99,183 | SEC↗ |
| Goater Jeff | Chief Executive Officer | M Exercise deriv | 2021-02-01 | 2021-02-03 | 2,500 | — | $0 | 249,500 | SEC↗ |
| FEES JESSICA | See Remarks | S Sale | 2021-02-01 | 2021-02-03 | 1,500 | $11.19 | $16.8K | 100,683 | SEC↗ |
| Goater Jeff | Chief Executive Officer | S Sale | 2021-02-01 | 2021-02-03 | 2,500 | $10.69 | $26.7K | 262,000 | SEC↗ |
| Goater Jeff | Chief Executive Officer | M Exercise | 2021-02-01 | 2021-02-03 | 2,500 | $3.18 | $8.0K | 264,500 | SEC↗ |
| Goater Jeff | Chief Executive Officer | M Exercise deriv | 2021-01-19 | 2021-01-21 | 5,000 | — | $0 | 252,000 | SEC↗ |
| Goater Jeff | Chief Executive Officer | S Sale | 2021-01-19 | 2021-01-21 | 5,000 | $13.00 | $65.0K | 262,000 | SEC↗ |
| Goater Jeff | Chief Executive Officer | M Exercise | 2021-01-19 | 2021-01-21 | 5,000 | $3.18 | $15.9K | 267,000 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | S Sale | 2021-01-15 | 2021-01-15 | 2,000 | $12.25 | $24.5K | 89,000 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | S Sale | 2021-01-14 | 2021-01-15 | 7,000 | $11.95 | $83.7K | 91,000 | SEC↗ |
| Atlas Venture Fund IX, L.P. | 10% Owner | S Sale | 2020-12-17 | 2020-12-21 | 1,700,000 | $18.10 | $30.77M | 2,945,453 | SEC↗ |
| GRAYZEL DAVID S. | Director | S Sale | 2020-12-17 | 2020-12-21 | 1,700,000 | $18.10 | $30.77M | 2,945,453 | SEC↗ |
| Atlas Venture Associates IX, L | 10% Owner | S Sale | 2020-12-17 | 2020-12-21 | 1,700,000 | $8.10 | $13.77M | 2,945,453 | SEC↗ |
| GRAYZEL DAVID S. | Director | S Sale | 2020-12-17 | 2020-12-21 | 1,700,000 | $8.10 | $13.77M | 2,945,453 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | S Sale | 2020-12-15 | 2020-12-17 | 1,000 | $10.48 | $10.5K | 98,000 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | S Sale | 2020-12-11 | 2020-12-15 | 1,405 | $10.05 | $14.1K | 99,000 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise deriv | 2020-11-25 | 2020-11-27 | 227 | — | $0 | 455 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise deriv | 2020-11-25 | 2020-11-27 | 173 | — | $0 | 13,905 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise deriv | 2020-11-25 | 2020-11-27 | 982 | — | $0 | 2,654 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise deriv | 2020-11-25 | 2020-11-27 | 1 | — | $0 | 25,999 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise | 2020-11-25 | 2020-11-27 | 982 | $5.41 | $5.3K | 102,182 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise | 2020-11-25 | 2020-11-27 | 227 | $4.14 | $940 | 101,027 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise | 2020-11-25 | 2020-11-27 | 173 | $4.27 | $739 | 101,200 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise | 2020-11-25 | 2020-11-27 | 1 | $4.27 | $4 | 102,183 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | S Sale | 2020-11-11 | 2020-11-13 | 595 | $10.05 | $6.0K | 100,405 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise deriv | 2020-10-28 | 2020-10-30 | 122 | — | $0 | 14,078 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise deriv | 2020-10-28 | 2020-10-30 | 4,773 | — | $0 | 682 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise | 2020-10-28 | 2020-10-30 | 122 | $4.27 | $521 | 100,800 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise | 2020-10-28 | 2020-10-30 | 4,773 | $4.14 | $19.8K | 100,678 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | S Sale | 2020-10-14 | 2020-10-16 | 4,000 | $10.05 | $40.2K | 101,000 | SEC↗ |
| EcoR1 Capital, LLC | 10% Owner | S Sale | 2020-09-01 | 2020-09-03 | 332,780 | $7.14 | $2.38M | 4,701,081 | SEC↗ |
| Shanafelt Armen | Director, 10% Owner | A Award deriv | 2020-06-10 | 2020-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| LYNCH DANIEL | Director | A Award deriv | 2020-06-10 | 2020-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| MCDONOUGH GEOFF | Director | A Award deriv | 2020-06-10 | 2020-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2020-06-10 | 2020-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| Stelzer Laurie | Director | A Award deriv | 2020-06-10 | 2020-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| Ibrahim Ramy | Director | A Award deriv | 2020-06-10 | 2020-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| Sigal Charles Elliott | Director | A Award deriv | 2020-06-10 | 2020-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| Florence Anthony A. Jr. | 10% Owner | S Sale | 2020-05-20 | 2020-05-22 | 420,000 | $3.66 | $1.54M | 2,892,877 | SEC↗ |
| ONEILL ALISON | Chief Medical Officer | A Award | 2020-03-01 | 2022-01-14 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Dwyer Wendy | Chief Business Officer | A Award | 2020-02-28 | 2020-03-03 | 5,000 | $1.70 | $8.5K | 85,000 | SEC↗ |
| Goater Jeff | Chief Executive Officer | P Buy | 2020-02-05 | 2020-02-07 | 5,000 | $3.23 | $16.1K | 262,000 | SEC↗ |
| Goater Jeff | Chief Executive Officer | A Award deriv | 2020-02-03 | 2020-02-05 | 257,000 | — | $0 | 257,000 | SEC↗ |
| FEES JESSICA | See Remarks | A Award deriv | 2020-02-03 | 2020-02-05 | 45,000 | — | $0 | 45,000 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | A Award deriv | 2020-02-03 | 2020-02-05 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Dwyer Wendy | Chief Business Officer | A Award deriv | 2020-02-03 | 2020-02-05 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | A Award deriv | 2020-02-03 | 2020-02-05 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Nogelo Liisa I | Chief Legal Officer | A Award deriv | 2020-02-03 | 2020-02-05 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Goater Jeff | Chief Executive Officer | A Award | 2020-02-03 | 2020-02-05 | 257,000 | — | $0 | 257,000 | SEC↗ |
| FEES JESSICA | See Remarks | A Award | 2020-02-03 | 2020-02-05 | 45,000 | — | $0 | 95,905 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | A Award | 2020-02-03 | 2020-02-05 | 80,000 | — | $0 | 105,000 | SEC↗ |
| Dwyer Wendy | Chief Business Officer | A Award | 2020-02-03 | 2020-02-05 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | A Award | 2020-02-03 | 2020-02-05 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Nogelo Liisa I | Chief Legal Officer | A Award | 2020-02-03 | 2020-02-05 | 80,000 | — | $0 | 80,000 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2019-10-01 | 2019-10-03 | 14,965 | — | $0 | 14,965 | SEC↗ |
| Ibrahim Ramy | Director | A Award deriv | 2019-10-01 | 2019-10-03 | 24,200 | — | $0 | 24,200 | SEC↗ |
| MCDONOUGH GEOFF | Director | A Award deriv | 2019-10-01 | 2019-10-03 | 9,135 | — | $0 | 9,135 | SEC↗ |
| Shanafelt Armen | Director, 10% Owner | A Award deriv | 2019-10-01 | 2019-10-03 | 16,531 | — | $0 | 16,531 | SEC↗ |
| Sigal Charles Elliott | Director | A Award deriv | 2019-10-01 | 2019-10-03 | 13,572 | — | $0 | 13,572 | SEC↗ |
| Sigal Charles Elliott | Director | A Award deriv | 2019-07-01 | 2019-07-02 | 5,696 | — | $0 | 5,696 | SEC↗ |
| Shanafelt Armen | Director, 10% Owner | A Award deriv | 2019-07-01 | 2019-07-02 | 6,937 | — | $0 | 6,937 | SEC↗ |
| MCDONOUGH GEOFF | Director | A Award deriv | 2019-07-01 | 2019-07-02 | 3,834 | — | $0 | 3,834 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2019-07-01 | 2019-07-02 | 6,280 | — | $0 | 6,280 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2019-06-05 | 2019-06-06 | 12,100 | — | $0 | 12,100 | SEC↗ |
| LYNCH DANIEL | Director | A Award deriv | 2019-06-05 | 2019-06-06 | 12,100 | — | $0 | 12,100 | SEC↗ |
| MCDONOUGH GEOFF | Director | A Award deriv | 2019-06-05 | 2019-06-06 | 12,100 | — | $0 | 12,100 | SEC↗ |
| Shanafelt Armen | Director, 10% Owner | A Award deriv | 2019-06-05 | 2019-06-06 | 12,100 | — | $0 | 12,100 | SEC↗ |
| Sigal Charles Elliott | Director | A Award deriv | 2019-06-05 | 2019-06-06 | 12,100 | — | $0 | 12,100 | SEC↗ |
| Stelzer Laurie | Director | A Award deriv | 2019-06-05 | 2019-06-06 | 12,100 | — | $0 | 12,100 | SEC↗ |
| Dwyer Wendy | Chief Business Officer | A Award deriv | 2019-05-01 | 2019-05-02 | 125,000 | — | $0 | 125,000 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise deriv | 2019-04-01 | 2019-04-02 | 2,728 | — | $0 | 0 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise | 2019-04-01 | 2019-04-02 | 2,728 | $0.35 | $955 | 50,905 | SEC↗ |
| Goater Jeff | Chief Executive Officer | A Award deriv | 2019-03-01 | 2019-03-04 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Nogelo Liisa I | General Counsel | A Award deriv | 2019-03-01 | 2019-03-04 | 80,000 | — | $0 | 80,000 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | A Award deriv | 2019-03-01 | 2019-03-04 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Palombella Vito J. | Chief Scientific Officer | A Award deriv | 2019-03-01 | 2019-03-04 | 90,000 | — | $0 | 90,000 | SEC↗ |
| FEES JESSICA | See Remarks | A Award deriv | 2019-03-01 | 2019-03-04 | 14,200 | — | $0 | 14,200 | SEC↗ |
| FEES JESSICA | See Remarks | A Award deriv | 2019-03-01 | 2019-03-04 | 26,000 | — | $0 | 26,000 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise deriv | 2019-01-04 | 2019-01-08 | 1,818 | — | $0 | 2,728 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise deriv | 2019-01-04 | 2019-01-08 | 455 | — | $0 | 5,455 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | M Exercise deriv | 2019-01-04 | 2019-01-08 | 25,000 | — | $0 | 256,578 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise | 2019-01-04 | 2019-01-08 | 1,818 | $0.35 | $636 | 47,722 | SEC↗ |
| FEES JESSICA | See Remarks | M Exercise | 2019-01-04 | 2019-01-08 | 455 | $4.14 | $1.9K | 48,177 | SEC↗ |
| ROSS ROBERT W. | Chief Medical Officer | M Exercise | 2019-01-04 | 2019-01-08 | 25,000 | $4.14 | $103.5K | 25,000 | SEC↗ |
| Nogelo Liisa I | General Counsel | A Award deriv | 2018-08-01 | 2018-08-01 | 115,000 | — | $0 | 115,000 | SEC↗ |
| Sigal Charles Elliott | Director | A Award deriv | 2018-07-02 | 2018-07-05 | 8,882 | — | $0 | 8,882 | SEC↗ |
| Sigal Charles Elliott | Director | C Conversion deriv | 2018-04-23 | 2018-04-23 | 100,000 | — | $0 | 0 | SEC↗ |
| Shanafelt Armen | Director, 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 7,000,000 | — | $0 | 0 | SEC↗ |
| Hall Steven Edward | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 7,000,000 | — | $0 | 0 | SEC↗ |
| GRAYZEL DAVID S. | Director | C Conversion deriv | 2018-04-23 | 2018-04-23 | 7,000,000 | — | $0 | 0 | SEC↗ |
| Atlas Venture Associates IX, L | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 7,000,000 | — | $0 | 0 | SEC↗ |
| Novartis Institutes for BioMed | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 1,571,429 | — | $0 | 0 | SEC↗ |
| Novartis Institutes for BioMed | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 5,214,286 | — | $0 | 0 | SEC↗ |
| New Enterprise Associates 14, | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| BARRETT M JAMES | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| BARRIS PETER J | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| BASKETT FOREST | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| Florence Anthony A. Jr. | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| KERINS PATRICK J | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| MOTT DAVID M | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| Sonsini Peter W. | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| Viswanathan Ravi | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-23 | 6,995,000 | — | $0 | 0 | SEC↗ |
| October 2017 Liquidating Trust | Other | C Conversion deriv | 2018-04-23 | 2018-04-25 | 893,450 | — | $0 | 0 | SEC↗ |
| FMR LLC | 10% Owner | C Conversion deriv | 2018-04-23 | 2018-04-25 | 4,155,773 | — | $0 | 0 | SEC↗ |
| FIL Ltd | Other | C Conversion deriv | 2018-04-23 | 2018-04-25 | 1,950,777 | — | $0 | 0 | SEC↗ |
| Sigal Charles Elliott | Director | C Conversion | 2018-04-23 | 2018-04-23 | 45,453 | — | $0 | 45,453 | SEC↗ |
| Shanafelt Armen | Director, 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,181,817 | — | $0 | 3,181,817 | SEC↗ |
| Shanafelt Armen | Director, 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 266,000 | $15.00 | $3.99M | 3,447,817 | SEC↗ |
| Hall Steven Edward | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 266,000 | $15.00 | $3.99M | 3,447,817 | SEC↗ |
| Hall Steven Edward | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,181,817 | — | $0 | 3,181,817 | SEC↗ |
| GRAYZEL DAVID S. | Director | P Buy | 2018-04-23 | 2018-04-23 | 100,000 | $15.00 | $1.50M | 4,645,453 | SEC↗ |
| GRAYZEL DAVID S. | Director | C Conversion | 2018-04-23 | 2018-04-23 | 3,181,817 | — | $0 | 4,545,453 | SEC↗ |
| Atlas Venture Associates IX, L | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,181,817 | — | $0 | 4,545,453 | SEC↗ |
| Atlas Venture Associates IX, L | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 100,000 | $15.00 | $1.50M | 4,645,453 | SEC↗ |
| Novartis Institutes for BioMed | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 909,090 | — | $0 | 3,181,816 | SEC↗ |
| Novartis Institutes for BioMed | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 2,272,726 | — | $0 | 2,272,726 | SEC↗ |
| Novartis Institutes for BioMed | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 766,666 | $15.00 | $11.50M | 3,948,482 | SEC↗ |
| New Enterprise Associates 14, | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| New Enterprise Associates 14, | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| BARRETT M JAMES | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| BARRETT M JAMES | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| BARRIS PETER J | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| BARRIS PETER J | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| BASKETT FOREST | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| BASKETT FOREST | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| Florence Anthony A. Jr. | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| Florence Anthony A. Jr. | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| KERINS PATRICK J | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| KERINS PATRICK J | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| MOTT DAVID M | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| MOTT DAVID M | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| SANDELL SCOTT D | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| Sonsini Peter W. | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| Sonsini Peter W. | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| Viswanathan Ravi | 10% Owner | P Buy | 2018-04-23 | 2018-04-23 | 133,333 | $15.00 | $2.00M | 3,312,877 | SEC↗ |
| Viswanathan Ravi | 10% Owner | C Conversion | 2018-04-23 | 2018-04-23 | 3,179,544 | — | $0 | 3,179,544 | SEC↗ |
| October 2017 Liquidating Trust | Other | C Conversion | 2018-04-23 | 2018-04-25 | 406,113 | — | $0 | 406,113 | SEC↗ |
| FMR LLC | 10% Owner | C Conversion | 2018-04-23 | 2018-04-25 | 1,888,986 | — | $0 | 1,888,986 | SEC↗ |
| FIL Ltd | Other | C Conversion | 2018-04-23 | 2018-04-25 | 886,716 | — | $0 | 886,716 | SEC↗ |